Search

Your search keyword '"Øvlisen, Andreas K."' showing total 13 results
Start Over Author "Øvlisen, Andreas K." Publication Year Range Last 10 years

Refine your results

more »

more »

more »
13 results on '"Øvlisen, Andreas K."'

1. Risk of diabetes and the impact on preexisting diabetes in patients with lymphoma treated with steroid-containing immunochemotherapy

Author

Baech, Joachim, Severinsen, Marianne Tang, Øvlisen, Andreas K., Frederiksen, Henrik, Vestergaard, Peter, Torp-Pedersen, Christian, Jørgensen, Judit, Clausen, Michael Roost, Poulsen, Christian B., Brown, Peter, Gang, Anne Ortved, Pedersen, Robert Schou, Ekström Smedby, Karin, Eloranta, Sandra, Jakobsen, Lasse Hjort, and El-Galaly, Tarec Christoffer

Published
2022
Full Text
View/download PDF

2. Stringent or nonstringent complete remission and prognosis in acute myeloid leukemia: a Danish population-based study

Author

Øvlisen, Andreas K., Oest, Anders, Bendtsen, Mette D., Bæch, John, Johansen, Preben, Lynggaard, Line S., Mølle, Ingolf, Mortensen, Thomas B., Weber, Duruta, Ertner, Gideon, Schöllkopf, Claudia, Thomassen, Jesper Q., Nielsen, Ove Juul, Østgård, Lene Sofie Granfeldt, Bøgsted, Martin, Dybkær, Karen, Johnsen, Hans E., and Severinsen, Marianne T.

Published
2018
Full Text
View/download PDF

3. Reproduction patterns among non‐Hodgkin lymphoma survivors by subtype in Sweden, Denmark and Norway: A population‐based matched cohort study

Author

Entrop, Joshua P., primary, Weibull, Caroline E., additional, Smedby, Karin E., additional, Jakobsen, Lasse H., additional, Øvlisen, Andreas K., additional, Glimelius, Ingrid, additional, Marklund, Anna, additional, Larsen, Thomas S., additional, Holte, Harald, additional, Fosså, Alexander, additional, Smeland, Knut B., additional, El‐Galaly, Tarec C., additional, and Eloranta, Sandra, additional

Published
2023
Full Text
View/download PDF

4. Reproduction patterns among non-Hodgkin lymphoma survivors by subtype in Sweden, Denmark and Norway:A population-based matched cohort study

Author

Entrop, Joshua P., Weibull, Caroline E., Smedby, Karin E., Jakobsen, Lasse H., Øvlisen, Andreas K., Glimelius, Ingrid, Marklund, Anna, Larsen, Thomas S., Holte, Harald, Fosså, Alexander, Smeland, Knut B., El-Galaly, Tarec C., and Eloranta, Sandra

Subjects
fertility, non-Hodgkin lymphoma, late effects of therapy
Abstract

Previous studies concerning reproductive patterns among non-Hodgkin lymphoma (NHL) survivors are scarce and those available have reported conflicting results. Treatment regimens vary considerably between aggressive and indolent NHL and studies of reproductive patterns by subtypes are warranted. In this matched cohort study, we identified all NHL patients aged 18–40 years and diagnosed between 2000 and 2018 from the Swedish and Danish lymphoma registers, and the clinical database at Oslo University Hospital (n = 2090). Population comparators were matched on sex, birth year and country (n = 19 427). Hazard ratios (HRs) were estimated using Cox regression. Males and females diagnosed with aggressive lymphoma subtypes had lower childbirth rates (HRfemale: 0.43, 95% CI: 0.31–0.59, HRmale: 0.61, 95% CI: 0.47–0.78) than comparators during the first 3 years after diagnosis. For indolent lymphomas, childbirth rates were not significantly different from comparators (HRfemale: 0.71, 95% CI: 0.48–1.04, HRmale: 0.94, 95% CI: 0.70–1.27) during the same period. Childbirth rates reached those of comparators for all subtypes after 3 years but the cumulative incidence of childbirths was decreased throughout the 10-year follow-up for aggressive NHL. Children of NHL patients were more likely to be born following assisted reproductive technology than those of comparators, except for male indolent lymphoma patients. In conclusion, fertility counselling is particularly important for patients with aggressive NHL.

Published
2023
Full Text
View/download PDF

5. Reproduction patterns among classical Hodgkin lymphoma survivors treated with BEACOPP and ABVD in Sweden, Denmark and Norway-A population-based matched cohort study

Author

Entrop, Joshua P., Weibull, Caroline E., Smedby, Karin E., Jakobsen, Lasse H., Øvlisen, Andreas K., Molin, Daniel, Glimelius, Ingrid, Marklund, Anna, Holte, Harald, Fosså, Alexander, Smeland, Knut B., El-Galaly, Tarec C., Eloranta, Sandra, Entrop, Joshua P., Weibull, Caroline E., Smedby, Karin E., Jakobsen, Lasse H., Øvlisen, Andreas K., Molin, Daniel, Glimelius, Ingrid, Marklund, Anna, Holte, Harald, Fosså, Alexander, Smeland, Knut B., El-Galaly, Tarec C., and Eloranta, Sandra

Abstract

Childbirth rates in classical Hodgkin lymphoma (cHL) survivors have historically been reduced compared to the general population. Understanding if contemporary treatment protocols are associated with reduced fertility is crucial as treatment guidelines shift toward more liberal use of intensive chemotherapy. We identified 2834 individuals aged 18-40 years with cHL in Swedish and Danish lymphoma registers, and in the clinical database at Oslo University Hospital diagnosed 1995-2018, who were linked to national medical birth registers. Cox regression adjusted for stage, performance status, year, and age at diagnosis was used to estimate hazard ratios (HRs) and 95% confidence intervals (CI) contrasting time to first childbirth by treatment groups (ABVD, 2-4 BEACOPP, 6-8 BEACOPP) up to 10 years after diagnosis. Overall, 74.8% of patients were treated with ABVD, 3.1% with 2-4 BEACOPP and 11.2% with 6-8 BEACOPP. Adjusted HRs comparing childbirth rates in individuals treated with 6-8 BEACOPP, and 2-4 BEACOPP to ABVD were 0.53 (CI: 0.36-0.77) and 0.33 (CI: 0.12-0.91) for males, and 0.91 (CI: 0.61-1.34) and 0.38 (CI: 0.12-1.21) for females. Cumulative incidence of childbirths after 10 years was 19.8% (CI: 14.5%-27.0%) for males and 34.3% (CI: 25.8%-45.6%) for females treated with 6-8 BEACOPP. Proportions of children born after assisted reproductive technique (ART) treatments were 77.4% (CI: 60.2-88.6%) for males following 6-8 BEACOPP, and <11% for females. Among ABVD treated patients the corresponding proportions were 12.2% (CI: 8.5%-17.3%) and 10.6% (CI: 7.4%-14.9%). BEACOPP treatment is associated with decreased childbirth rates compared to ABVD in male, but not female, cHL patients, despite widespread access to ART in the Nordics.

Published
2023
Full Text
View/download PDF

6. Reproduction patterns among classical Hodgkin lymphoma survivors treated with BEACOPP and ABVD in Sweden, Denmark and Norway—A population‐based matched cohort study

Author

Entrop, Joshua P., primary, Weibull, Caroline E., additional, Smedby, Karin E., additional, Jakobsen, Lasse H., additional, Øvlisen, Andreas K., additional, Molin, Daniel, additional, Glimelius, Ingrid, additional, Marklund, Anna, additional, Holte, Harald, additional, Fosså, Alexander, additional, Smeland, Knut B., additional, El‐Galaly, Tarec C., additional, and Eloranta, Sandra, additional

Published
2023
Full Text
View/download PDF

7. T065: Reproduction patterns among Classical Hodgkin Lymphoma Survivors Treated with BEACOPP and ABVD in Sweden, Denmark, and Norway

Author

Entrop, Joshua P., primary, Weibull, Caroline E., additional, Smedby, Karin E., additional, Jakobsen, Lasse Hjort, additional, øvlisen, Andreas K., additional, Molin, Daniel, additional, Glimelius, Ingrid, additional, Marklund, Anna, additional, Holte, Harald, additional, Fosså, Alexander, additional, Smeland, Knut B., additional, El-Galaly, Tarec Christoffer, additional, and Eloranta, Sandra, additional

Published
2022
Full Text
View/download PDF

8. Parenthood Rates and Use of Assisted Reproductive Techniques in Younger Hodgkin Lymphoma Survivors: A Danish Population-Based Study

Author

Øvlisen, Andreas K., primary, Jakobsen, Lasse H., additional, Eloranta, Sandra, additional, Kragholm, Kristian H., additional, Hutchings, Martin, additional, Frederiksen, Henrik, additional, Kamper, Peter, additional, Dahl-Sørensen, Rasmus Bo, additional, Stoltenberg, Danny, additional, Weibull, Caroline E., additional, Entrop, Joshua P., additional, Glimelius, Ingrid, additional, Smedby, Karin E., additional, Torp-Pedersen, Christian, additional, Severinsen, Marianne T., additional, and El-Galaly, Tarec C., additional

Published
2021
Full Text
View/download PDF

10. Depression and anxiety in Hodgkin lymphoma patients: A Danish nationwide cohort study of 945 patients

Author

Øvlisen, Andreas K., primary, Jakobsen, Lasse H., additional, Kragholm, Kristian H., additional, Nielsen, René E., additional, Hutchings, Martin, additional, Dahl‐Sørensen, Rasmus B., additional, Frederiksen, Henrik, additional, Stoltenberg, Danny, additional, Bøgsted, Martin, additional, Østgård, Lene S. G., additional, Severinsen, Marianne T., additional, and El‐Galaly, Tarec C., additional

Published
2020
Full Text
View/download PDF

11. Increased risk of osteoporosis following commonly used first-line treatments for lymphoma: a Danish Nationwide Cohort Study

Author

Baech, Joachim, primary, Hansen, Steen Moeller, additional, Jakobsen, Lasse Hjort, additional, Øvlisen, Andreas K., additional, Severinsen, Marianne Tang, additional, Brown, Peter de Nully, additional, Vestergaard, Peter, additional, Frederiksen, Henrik, additional, Jørgensen, Judit, additional, Starklint, Jørn, additional, Josefsson, Pär, additional, Hammer, Troels, additional, Clausen, Michael Roost, additional, Torp-Pedersen, Christian, additional, Jensen, Paw, additional, and El-Galaly, Tarec Christoffer, additional

Published
2020
Full Text
View/download PDF

12. Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real‐world patients

Author

Jakobsen, Lasse H., primary, Ellin, Fredrik, additional, Smeland, Knut B., additional, Wästerlid, Tove, additional, Christensen, Jacob H., additional, Jørgensen, Judit M., additional, Josefsson, Pär L., additional, Øvlisen, Andreas K., additional, Holte, Harald, additional, Blaker, Yngvild N., additional, Grauslund, Jacob H., additional, Bjørn, Jon, additional, Molin, Daniel, additional, Lagerlöf, Ingemar, additional, Smedby, Karin E., additional, Colvin, Katherine, additional, Thanarajasingam, Gita, additional, Maurer, Matthew J., additional, Habermann, Thomas M., additional, Song, Kevin W., additional, Zhu, Katie Y., additional, Gerrie, Alina S., additional, Cheah, Chan Y., additional, and El‐Galaly, Tarec C., additional

Published
2020
Full Text
View/download PDF

13. Increased risk of osteoporosis following commonly used first-line treatments for lymphoma:a Danish Nationwide Cohort Study

Author

Baech, Joachim, Hansen, Steen Moeller, Jakobsen, Lasse Hjort, Øvlisen, Andreas K, Severinsen, Marianne Tang, Brown, Peter de Nully, Vestergaard, Peter, Frederiksen, Henrik, Jørgensen, Judit, Starklint, Jørn, Josefsson, Pär, Hammer, Troels, Clausen, Michael Roost, Torp-Pedersen, Christian, Jensen, Paw, El-Galaly, Tarec Christoffer, Baech, Joachim, Hansen, Steen Moeller, Jakobsen, Lasse Hjort, Øvlisen, Andreas K, Severinsen, Marianne Tang, Brown, Peter de Nully, Vestergaard, Peter, Frederiksen, Henrik, Jørgensen, Judit, Starklint, Jørn, Josefsson, Pär, Hammer, Troels, Clausen, Michael Roost, Torp-Pedersen, Christian, Jensen, Paw, and El-Galaly, Tarec Christoffer

Abstract

High-dose prednisolone is used in first-line treatment for lymphoma, but the potential adverse impact on bone health is unclear. Danish patients with diffuse large B-cell lymphoma or follicular lymphoma diagnosed between 2000 and 2012 were matched to the background population. Osteoporotic events (osteoporosis treatment or low-energy fracture) were identified using the Danish National Patient Registry and Prescription Registry. In total, 2589 patients and 12,945 controls were included. Lymphoma patients had increased risk of osteoporotic events compared to the matched population (hazard ratio 1.61 [95% confidence interval 1.40;1.84]). The 5- and 10-year cumulative risks of osteoporotic events for lymphoma patients were 10.0% [8.6;11.4] and 16.3% [13.8;18.7], whereas corresponding risks in the background population were 6.8% [6.3;7.3] and 13.5% [12.4;14.6]. Patients without osteoporotic event in the first two years after treatment were not at higher risk of osteoporotic events in subsequent years. Risk factors for osteoporotic events were female sex and age >70 years.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results